
Pathologic clues for the diagnosis of Erdheim Chester Disease (ECD)

What is ECD?

- A clonal proliferation of histiocytes that has a xanthogranuloma (XG) phenotype with a distinctive clinicoradiographic presentation.
- ECD now recognized as a distinct entity in the updated 2016/2017 WHO tumors of hematopoietic and lymphoid tissues.
- Accumulating data support ECD as a clonal inflammatory myeloid neoplasm, similar to LCH.
- Proposed "L" (Langerhans) grouping in the 2016 Blood revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell linages.



- Dr. Jennifer Picarsic and Dr. Ronald Jaffe, University of Pittsburgh School of Medicine
 - on behalf of the Erdheim Chester Disease (ECD) Global Alliance

Varied morphology:

Epithelioid, xanthomatous, or spindled histiocytes, +/- fibrosis

Immunophenotype of XG family:

- CD14 (surface) ullet

Ancillary molecular testing:

- identified

• CD68 (granular cytoplasmic) CD163 (surface/cytoplasmic)

Fascin and Factor XIIIa (cyto)

VE1 (dark cytoplasmic granular) in *BRAF*-V600E mutated cases

Little to negative S100

• Negative CD1a and Langerin

Mutations in *BRAF*, *MAP2K1*, NRAS, PIK3CA, and gene fusions

BRAF testing to include sensitive methods (<1% allele) for accurate detection, especially given the variable low content of clonal histiocytes in some cases.